spacer
home > ict > autumn 2009 > equipped for success
PUBLICATIONS
International Clinical Trials

Equipped for Success

 

Over recent years, many good articles have been written about outsourcing in clinical studies. Most of these refer to outsourcing of trials by pharma companies to clinical research organisations, and cover all aspects from cost benefit analysis, supplier selection process, scorecards, performance measurement and management of customer and supplier relationships. At the risk of being inundated with responses from readers advising me to the contrary, I cannot recollect reading any articles regarding outsourcing of a company’s medical equipment requirements for clinical studies to a single supplier.

In many ways, this is understandable, as initiation of an outsourcing project is often instigated by senior levels within a business such as board members and directors. For the majority of clinical trials, the total cost of medical equipment is a very low figure, often less than two per cent of the trial cost. For this reason, medical equipment will rarely appear on senior management’s radar unless it has been the cause of serious delays or caused impairment of the results of a trial.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

David Maughan is Managing Director of Medical Equipment Supplies and Management Ltd (MESM), a global supplier of medical equipment to the clinical trials industry. David is also a non-executive director of the Optare Group (bus manufacturer), board member of the Northwest Industrial Development Board and also of the North-west Automotive Alliance. David spent 30 years working in the automotive sector in various procurement roles, the most recent being 10 years as Purchasing Director of Bentley motor cars, part of the VW Group. During that time he was a member of the corporate sourcing committee for all group purchases.

spacer
David Maughan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Rousselot® Biomedical Announces the Launch of Quali-Pure HGP 2000

Irving, United States, May 4 2022 / Sciad Newswire / Rousselot®, Darling Ingredients’ health brand and the global leader of collagen-based solutions1, launches Quali-Pure™ HGP 2000, a new endotoxin-controlled, pharmaceutical-grade gelatin specifically designed for vaccines and wound healing applications. As the latest addition to Rousselot Biomedical’s rapidly expanding product offering, this new non-gelling hydrolyzed gelatin further extends the scope of biomedical applications covered by Rousselot products.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement